Detalle Publicación

ARTÍCULO

A road map for the treatment of pediatric diffuse midline glioma

Autores: Koschmann, C. (Autor de correspondencia); Al-Holou, W. N.; Alonso Roldán, Marta María; Anastas, J.; Bandopadhayay, P.; Barron, T.; Becher, O.; Cartaxo, R.; Castro, M. G.; Chung, C.; Clausen, M.; Dang, D.; Doherty, R.; Duchatel, R.; Dun, M.; Filbin, M.; Franson, A.; Galban, S.; García Moure, Marc; Garton, H.; Gowda, P.; Marques, J. G.; Hawkins, C.; Heath, A.; Hulleman, E.; Ji, S. J.; Jones, C.; Kilburn, L.; Kline, C.; Koldobskiy, M. A.; Lim, D.; Lowenstein, P. R.; Lu, Q. R.; Lum, J.; Mack, S.; Magge, S.; Marini, B.; Messinger, D.; Martin, D.; Marupudi, N.; Mody, R.; Morgan, M.; Mota, M.; Muraszko, K.; Mueller, S.; Natarajan, S. K.; Nazarian, J.; Niculcea, M.; Nuechterlein, N.; Okada, H.
Título de la revista: CANCER CELL
ISSN: 1535-6108
Volumen: 42
Número: 1
Páginas: 1 - 5
Fecha de publicación: 2024
Resumen:
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.
DOI: https://doi.org/10.1016/j.ccell.2023.11.002
Impacto:
Google Scholar